Article Text


A1.7 Interferon and B-Cell Gene Signatures Contribute to Diagnosis of Pre-Clinical Rheumatoid Arthritis
  1. Joyce Lubbers1,
  2. Lotte A van de Stadt2,
  3. Saskia Vosslamber1,
  4. John G Wesseling1,
  5. Senay Oztürk1,
  6. Dirkjan van Schaardenburg2,
  7. Cornelis L Verweij1
  1. 1VU University Medical Center, Amsterdam, Netherlands
  2. 2Jan van Breemen Research Institute, Reade, Amsterdam, Netherlands


Background/Objective Early diagnosis of the preclinical phase of rheumatoid arthritis (pre-RA) allows timely start of treatment with the potential to prevent disease progression. It is known that antibodies against citrullinated proteins (ACPA) and rheumatoid factor (RF) have diagnostic value to identify pre-RA. However, since only 20–40% of ACPA+/RF+ arthralgia patients develop arthritis within 5 years, better prognostic markers are needed. Recently, we demonstrated involvement of interferon (IFN) response and B-cell gene signatures in pre-RA. The objective is to demonstrate the value of these signatures to diagnose pre-RA.

Methods Peripheral blood (Paxgene) was collected from 115 ACPA+/RF+ arthralgia patients who were clinically followed for arthritis development, one or more swollen joints, with a mean follow-up time of 23 months (IQR 12–30). An IFN and B-cell score was calculated based on 7 Type I IFN response genes and 3 B-cell related genes, respectively, measured by multiplex qPCR. Cox regression analysis and Receiver Operating Characteristic (ROC)-curve analysis were used to demonstrate prognostic and diagnostic significance.

Results Out of 115 arthralgia patients 44 developed arthritis after a median time of 8 months (IQR 5–13). Stratification of these individuals based on the IFN score revealed that 60% of the IFNhigh patients converted to arthritis compared to 32% in IFNlow patients (P = 0.011). For the B-cell signature, 58% in B-celllow patients developed arthritis, compared to 33% of B-cellhigh patients (P = 0.020). Combined analysis revealed a significant high risk for arthritis development in IFNhigh/B-celllow patients (80%, hazard ratio (HR) 6.22, P = 0.003) and a low risk for IFNlow/B-cellhigh patients (26%, HR 0.16, P = 0.003). To demonstrate clinical utility a ROC-curve was constructed of ACPA+/RF+ alone and in combination with both signatures. The area under the curve reached 0.619 (P = 0.032, CI 0.514–0.724) for ACPA+/RF+ and increased to 0.803 (P = 0.0001, CI 0.718–0.888) with IFN and B-cell signatures included. The sensitivity to diagnose pre-RA increased from 16% to 52% when both signatures are included, with a cut-off of 94% specificity.

Conclusions These findings demonstrate the clinical value of IFN and B-cell gene signatures as biomarkers for the diagnosis of pre-RA.

This research was supported by the Center for Translational Molecular Medicine (CTMM) consortium “TRACER”.

Statistics from

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.